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Background: In PARADIGM-HF, the angiotensin receptor neprilysin inhibitor (ARNI) 
sacubitril/valsartan was more effective than the ACE-I enalapril, in patients with heart failure 
and reduced ejection fraction. We examined whether this benefit was consistent irrespective of 
background therapy.  
 
Methods and Results: We examined the effect of study treatment in the following subgroups: 
diuretics (yes/no), digitalis glycoside (yes/no), mineralocorticoid receptor antagonist [MRA] 
(yes/no) and defibrillating device (implanted defibrillating-device, yes/no). We also examined 
the effect of study drug according to beta-blocker dose (≥50% and <50% of target dose) and 
according to whether or not patients had undergone previous coronary revascularization. We 
analysed the primary composite endpoint of cardiovascular (CV) death or HF hospitalization, as 
well as cardiovascular death. Most randomized patients (n=8399), were treated with a diuretic 
(80%) and beta-blocker (93%); 47% of those taking a beta-blocker were treated with ≥50% of 
the recommended dose. In addition, 4671 (56%) were treated with a MRA, 2539 (30%) with 
digoxin and 1243 (15%) had a defibrillating-device; 2640 (31%) had undergone coronary 
revascularization. Overall, the sacubitril/valsartan versus enalapril hazard ratio [HR] for the 
primary composite endpoint was 0.80 (95% CI 0.73-0.87), P<0.001 and for CV death 0.80 
(0.71-0.89), P<0.001. The effect of sacubitril/valsartan was consistent across all subgroups 
examined: the HR for primary endpoint ranged from 0.74 to 0.85 and for CV death from 0.75 to 
0.89, with no treatment by subgroup interaction. 
 
Conclusions: The benefit of sacubitril/valsartan, over an ACE inhibitor, was consistent regardless 
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Sacubitril/valsartan (formerly known as LCZ696) is a first-in-class angiotensin receptor neprilysin 
inhibitor shown to be superior to enalapril in patients with heart failure with reduced ejection 
fraction (HF-REF).1,2  As such, sacubitril/valsartan has been recommended as a more effective 
alternative to an angiotensin converting enzyme (ACE) inhibitor to be used in conjunction with 
other evidence-based treatments for this type of heart failure.3,4  Of course, it is of interest to 
know how the effect of sacubitril/valsartan compares with those of enalapril when combined with 
these other proven therapies. Here we examine outcomes in patients randomly assigned to 
sacubitril/valsartan, versus enalapril, according to background use of beta-blockers, 
mineralocorticoid receptor antagonists (MRAs), diuretics, digitalis glycosides implanted 






The background and results of PARADIGM-HF have been published.1-3 Briefly, PARADIGM-HF 
was a randomized, double-blind, and prospective comparison of sacubitril/valsartan with enalapril 
in patients with chronic HF-REF. Eligibility requirements at screening included an age of at least 
18 years, New York Heart Association (NYHA) functional class II-IV symptoms, and a left 
ventricular ejection fraction (LVEF) of 40% or less. Patients were required to be taking an ACE 
inhibitor or angiotensin receptor blocker (ARB) in a dose equivalent to enalapril 10 mg daily for 
at least 4 weeks before screening, along with a stable dose of a β-blocker (unless contraindicated 
or not tolerated) and a mineralocorticoid antagonist (MRA), if indicated. Exclusion criteria 
included symptomatic hypotension or systolic blood pressure <100 mm Hg at screening or <90 
mm Hg at randomization, estimated glomerular filtration rate <30 ml/min/1.73 m2, serum 
potassium >5.2 mmol/l at screening or >5.4 mmol/l at randomization, and unacceptable side 
effects to ACE inhibitors or ARBs. The trial was approved by the ethics committees at each 
institution participating in the trial and all patients gave written, informed consent. 
 
Trial outcomes 
The primary outcome of PARADIGM-HF was the composite of cardiovascular death or heart 
failure hospitalization and examination of each component of this composite was pre-specified. In 
this report we examine the effect of sacubitril/valsartan compared with enalapril on the primary 
outcome and cardiovascular death  
 
Background treatment subgroups 
We examined the effect of sacubitril/valsartan, compared with enalapril according to background 
pharmacological and device therapy. Subgroups were limited to those greater than 1000 and only 
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split into two groups to minimise the likelihood of a type 1 error. 15, 16 Therefore, the groups 
analysed included diuretics (yes/no), digitalis glycoside (yes/no), MRA (yes/no) and defibrillating 
device (implantable cardioverter-defibrillator or cardiac resynchronization therapy [CRT] plus 
defibrillator, yes/no). The subgroups of patients not taking a beta-blocker and without CRT were 
too small to analyse. We did, however, examine the effect of study drug according to beta-blocker 
dose, defined as ≥50% target dose and <50% of target dose. Target daily doses were taken from 
contemporary guidelines and included: carvedilol 50mg, bisoprolol 10mg, metoprolol succinate 
200mg, metoprolol tartrate 200mg, and nebivolol 10mg; patients (n=254) taking other 
beta-blockers were classified as taking <50% target dose. We also examined the effect of study 
drug according to whether or not patients had undergone previous coronary revascularization, 
given the evidence that surgical revascularization has beneficial effects on clinical outcomes.  
 
Statistical analysis 
The efficacy analyses were performed using a Cox proportional hazards model, including 
treatment and region. An analysis was performed in each subgroup and a treatment by subgroup 
interaction was tested. All analyses were performed using Stata version 14 (College Station, TX, 





The large majority of patients in PARADIGM-HF were treated with a diuretic (80%) and 
beta-blocker (93%); 3645 patients (47% of those taking a beta-blocker) were treated with ≥50% of 
a guideline recommended dose of beta-blocker. Of the 8399 patients randomized 4671 (56%) 
were treated with a MRA, 2539 (30%) with a digitalis glycoside and 1243 (15%) had a 
defibrillating device in situ. Overall, 2640 (31%) had a history of coronary revascularization.  
 
Figures 1and 2 show the cumulative incidence of the primary endpoint and of death from 
cardiovascular causes in each treatment subgroups examined. In each sub-group, the incidence of 
the primary endpoint in the enalapril group was higher in patients who received the background 
treatment of interest compared with those who did not. This finding was also observed in patients 
with prior coronary revascularization, compared with those who did not. The same pattern was 
observed for cardiovascular death with the exception of prior coronary revascularization. In 
patients with prior coronary revascularization the pattern was reversed, with a lower risk of death 
from cardiovascular causes compared with those who had not undergone coronary 
revascularization. In the case of beta-blockers, those receiving a lower dose had worse outcomes 
than those taking a higher dose. 
 
Table 1 summarizes the sacubitril/valsartan versus enalapril hazard ratio (HR) for the primary 
composite outcome of cardiovascular death or heart failure hospitalization, and cardiovascular 
death alone, according to background therapy. As can be seen, the benefit of sacubitril/valsartan 
over enalapril was consistent across all treatment subgroups, with no suggestion of a statistically 




As described in the Methods, we did not examine subgroups with less than one thousand patients 
because the increased play of chance with small numbers. We did, however, examine the effect of 
sacubitril/valsartan compared with enalapril according to background beta-blocker dose. The 
effect of sacubitril/valsartan, versus enalapril, was identical in patients treated with 50% or more 
of target doses of beta-blockers, compared to those treated with a lower dose (Table 1). 
 
Among patients with a defibrillating device, the effect of sacubitril/valsartan, versus enalapril, on 
both outcomes analyzed was similar to that in patients without such a device (Table 1).  
 
Lastly, patients with and without prior coronary revascularization also had a similar benefit of 
sacubitril/valsartan over enalapril (Table 1).   
 
There were a few minor differences in the baseline characteristics between treatment groups 
within each subgroup, however if corrected for multiple comparisons none are statistically 
significant (Supplemental Material). The estimate of effect of sacubitril/valsartan on the primary 






PARADIGM-HF was designed to compare sacubitril/valsartan to an ACE inhibitor in a broad 
spectrum of patients with HF-REF using the target dose of enalapril shown to reduce mortality, 
when compared to placebo, in the Studies Of Left Ventricular Dysfunction treatment trial 
(SOLVD-T).6 When SOLVD-T was conducted, background therapy consisted mainly of diuretics 
(85%) and a digitalis glycoside (67%); only 7.7% of patients were treated with a beta-blocker at 
baseline. 
 
Since the completion of SOLVD-T, digoxin has been shown to reduce the risk of hospital 
admission for worsening heart failure when added to an ACE inhibitor and, more importantly, 
other treatments, notably beta-blockers, and MRAs have been shown to reduce both mortality and 
hospitalization when used incrementally.7-12 Implantable cardioverter/defibrillators, which also 
reduce mortality, are another innovative treatment introduced since the time of SOLVD-T.13 
Lastly, the use of coronary revascularization has also become more prevalent since the time of 
SOLVD-T (31% of patients in PARADIGM-HF had undergone this compared with 21% patients 
in SOLVD-T) and has recently been shown to improve long-term survival in patients with 
HF-REF and obstructive epicardial coronary artery disease.14 Consequently, it is important to 
examine whether sacubitril/valsartan, proposed as a more effective alternative to an ACE 
inhibitor, had a consistent benefit over enalapril irrespective of contemporary background therapy. 
We have clearly shown that this is the case with respect to digitalis glycosides and MRAs. 
Because beta-blockers were used in the vast majority of patients we could not carry out a 
meaningful analysis of the effects of sacubitril/valsartan in individuals not receiving this 
treatment. We did, however, examine the effect of sacubitril/valsartan according to beta-blocker 
dose and found the benefit over enalapril was consistent irrespective of dose category. The 
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findings were similar for patients with and without an implanted defibrillating device and also for 
patients who had previously undergone coronary revascularization. 
 
In each treatment sub-group, the incidence of the primary endpoint was higher in patients who 
received the treatment of interest compared with those who did not, likely reflecting confounding 
by indication i.e. that these additional therapies were used in patients with more advanced heart 
failure (e.g. a severely and persistently reduced LVEF) or with comorbidities associated with 
worse outcomes (e.g. atrial fibrillation). The same was largely true for cardiovascular death with 
two exceptions. The rates of cardiovascular death were similar irrespective of defibrillating-device 
status, although there were relatively few events in those with such devices and limited power to 
show a difference between patients with and without a device. In patients with prior coronary 
revascularization, the rate of cardiovascular death was lower than in those without prior 
revascularization (i.e. the converse of what was seen for the primary endpoint). This may be a 
chance finding, reflect confounding by indication (surgery is more likely to be undertaken in 
healthier patients) or a powerful effect of revascularization on survival but not hospital admission. 
In the case of beta-blockers, the worse outcomes in those taking a lower dose may reflect 
confounding (sicker patients unable to tolerate higher doses) or a greater benefit from higher 
doses.17 
 
As with all analyses like these, there are limitations. Most of these subgroups were not 
pre-specified. Despite requiring each subgroup to include at least 1000 patients, such analyses are 
inherently underpowered. We could not examine the effect of sacubitril/valsartan compared with 
enalapril in patients receiving other evidence-based therapies.18,19 The use of evidence based, 
guideline directed therapies may have led to confounding by indication and geographic variations 
in their use may have led to further confounding. However, analyses of the geographic variation in 
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efficacy of sacubitril/valsartan confirmed that the efficacy of the drug did not vary by geographic 
region.3 Furthermore, our results were adjusted for geographic region as randomization was 
stratified by region and further adjustment made no difference to the findings.20 Only 574 patients 
had a CRT device implanted and both ivabradine and hydralazine combined with isosorbide 
dinitrate were used very infrequently. 
 
In summary, we found a consistent benefit of sacubitril/valsartan, over an ACE inhibitor, 
regardless of background therapy, including use of a diuretic, MRA, digoxin and implanted 
cardiac defibrillator. A similar benefit was also observed in patients with and without prior 
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LEGENDS TO TABLE AND FIGURES 
Table 1: Primary endpoint (composite of death from cardiovascular causes or hospitalization for 
heart failure) and death from cardiovascular causes according to treatment at baseline, 
history of coronary revascularization and baseline beta-blocker dose. 
 
Figure 1: Cumulative incidence of the primary endpoint (composite of death from cardiovascular 
causes or hospitalization for heart failure) in the enalapril and sacubitril/valsartan groups, 
according to background treatment (Figure 1a by diuretic therapy, Figure 1b by digoxin 
therapy, Figure 1c by mineralocorticoid receptor antagonist therapy, Figure 1d by 
implanted cardioverter defibrillator, Figure 1e by coronary revascularization, Figure 1f 
by betablocker dose above or below 50% of target). 
 
Figure 2: Cumulative incidence of death from cardiovascular causes in the enalapril and 
sacubitril/valsartan groups, according to background treatment (Figure 2a by diuretic 
therapy, Figure 2b by digoxin therapy, Figure 2c by mineralocorticoid receptor 
antagonist therapy, Figure 2d by implanted cardioverter defibrillator, Figure 2e by 








Table 1: Primary endpoint (composite of death from cardiovascular causes or hospitalization for heart failure) and death from 
cardiovascular causes according to baseline treatment, history of coronary revascularization and baseline beta-blocker dose. 
 
 








































































































































































































Figure 1a                    No Diuretic                            Diuretic 
                   
 
Figure 1b                    No Digoxin                             Digoxin 
                   
 
Figure 1c      No mineralocorticoid receptor antagonist      Mineralocorticoid receptor antagonist 












Figure 1d       No implanted cardioverter defibrillator        Implanted cardioverter defibrillator 
                     
 
Figure 1e       No prior coronary revascularization          Prior coronary revascularization 
                   
 
Figure 1f      Beta-blocker dose <50% target dose          Beta-blocker dose ≥50% target dose 















Figure 2a                    No Diuretic                            Diuretic 
                   
 
Figure 2b                    No Digoxin                             Digoxin 
                    
 
Figure 2c      No mineralocorticoid receptor antagonist      Mineralocorticoid receptor antagonist 












Figure 2d       No implanted cardioverter/defibrillator        Implanted cardioverter/defibrillator 
                   
 
Figure 2e       No prior coronary revascularization          prior coronary revascularization 
                   
 
Figure 2f      Beta-blocker dose <50% target dose          Beta-blocker dose ≥50% target dose 










Table 1: Baseline characteristics according to baseline diuretic  
 
 Diuretic (Yes) P value Diuretic (No) P value 
 Enalapril Sacubitril/valsartan  Enalapril Sacubitril/valsartan  
n (%) n=3375 (40) n=3363 (40)  n=837 (10) n=824 (10)  
Age, year 64 ± 11 64 ± 12 0.42 63 ± 11 64 ± 11 0.15 
Sex (female), n (%) 762    (22.6%) 715    (21.3%) 0.19 191    (22.8%) 164    (19.9%) 0.15 
Race, n (%)       
White 2268    (67.2%) 2262    (67.3%) 0.99 513    (61.3%) 501    (60.8%)  0.91 
Black 186    (5.5%) 188    (5.6%)  29     (3.5%) 25     (3.0%)  
Asian 557    (16.5%) 559    (16.6%)  193    (23.1%) 200    (24.3%)  
Other 364    (10.8%) 354    (10.5%)  102    (12.2%) 98     (11.9%)  
Region, n (%)       
North America 249    (7.4%) 239    (7.1%) 0.96 43     (5.1%) 71     (8.6%)  0.016 
Latin America 549    (16.3%) 567    (16.9%)  171    (20.4%) 146    (17.7%)  
Western Europe and 
other 857    (25.4%) 842    (25.0%) 
 
168    (20.1%) 184    (22.3%)  
Central Europe 1174    (34.8%) 1170    (34.8%)  259    (30.9%) 223    (27.1%)  
Asia 546    (16.2%) 545    (16.2%)  196    (23.4%) 200    (24.3%)  
Systolic blood pressure, 
mm Hg 121 ± 15 121 ± 15 
0.90 
121 ± 15 122 ± 15 0.04 
Heart rate, beats/min 73 ± 12 73 ± 12 0.35 71 ± 12 71 ± 12 0.50 
Body mass index, kg/m2 28 ± 6 28 ± 6 0.81 27 ± 5 27 ± 5 0.51 
Serum creatinine, mg/dL 1.13 ± 0.31 1.14 ± 0.31 0.32 1.08 ± 0.26 1.08 ± 0.26 0.86 
Clinical features of heart 
failure   
 
   
Left ventricular ejection 
fraction, % 29 ± 6 29 ± 6 0.22 30 ± 6 30 ± 6 0.23 













3423.5] 0.72 1348.0 [776.0, 2662.0] 
1287.5 [774.0, 
2459.0] 0.43 
NYHA functional class, n 
(%)   
 
   
I 134    (4.0%) 128    (3.8%) 0.22 75     (9.0%) 52     (6.3%)  0.11 
II 2308    (68.5%) 2361    (70.3%)  613    (73.4%) 637    (77.6%)  
III 905    (26.8%) 838    (24.9%)  144    (17.2%) 131    (16.0%)  
IV 24     (0.7%) 32     (1.0%)  3      (0.4%) 1      (0.1%)  
Ischemic etiology, n (%) 1979    (58.6%) 1953    (58.1%) 0.64 551    (65.8%) 553    (67.1%) 0.58 
Medical history, n (%)       
Hypertension 2417    (71.6%) 2405    (71.5%) 0.93 554    (66.2%) 564    (68.4%) 0.33 
Diabetes mellitus 1223    (36.2%) 1211    (36.0%) 0.85 233    (27.8%) 240    (29.1%) 0.56 
Atrial fibrillation 1321    (39.1%) 1283    (38.2%) 0.40 253    (30.2%) 234    (28.4%) 0.41 
Previous heart failure 
hospitalization 2196    (65.1%) 2183    (64.9%) 0.89 471    (56.3%) 424    (51.5%) 0.05 
Myocardial infarction 1416    (42.0%) 1395    (41.5%) 0.69 400    (47.8%) 423    (51.3%) 0.15 
Stroke 293    (8.7%) 273    (8.1%) 0.40 77     (9.2%) 82     (10.0%) 0.60 
Treatment at 
randomization, n (%)   
 
   
Previous use of ACE 
inhibitor 2638    (78.2%) 2649    (78.8%) 0.55 628    (75.0%) 617    (74.9%) 0.94 
Previous use of ARB 754    (22.3%) 720    (21.4%) 0.36 209    (25.0%) 209    (25.4%) 0.85 
Digitalis 1139    (33.7%) 1068    (31.8%) 0.08 177    (21.1%) 155    (18.8%) 0.23 
β-Blocker 3139    (93.0%) 3140    (93.4%) 0.56 773    (92.4%) 759    (92.1%) 0.85 
Mineralocorticoid 
antagonist 1980    (58.7%) 1898    (56.4%) 0.06 420    (50.2%) 373    (45.3%) 0.05 
Implantable cardioverter-
defibrillator 522    (15.5%) 507    (15.1%) 0.66 98     (11.7%) 116    (14.1%) 0.15 
Cardiac 
resynchronization therapy 244    (7.2%) 244    (7.3%) 0.97 38     (4.5%) 48     (5.8%) 0.24 
 
Table 2: Baseline characteristics according to baseline MRA 
 Mineralocorticoid antagonist (Yes) P value Mineralocorticoid antagonist (No) P value 
 Enalapril Sacubitril/valsartan  Enalapril Sacubitril/valsartan  
n (%) n=2400 (29) n=2271 (27)  n=1812 (22) n=1916 (23)  
Age, year 62 ± 11 62 ± 11 0.18 66 ± 11 66 ± 11 0.43 
Sex (female), n (%) 544    (22.7%) 482    (21.2%) 0.23 409    (22.6%) 397    (20.7%) 0.17 
Race, n (%)       
White 1562    (65.1%) 1480    (65.2%) 0.87 1219    (67.3%) 1283    (67.0%)  0.97 
Black 151    (6.3%) 140    (6.2%)  64     (3.5%) 73     (3.8%)  
Asian 426    (17.8%) 418    (18.4%)  324    (17.9%) 341    (17.8%)  
Other 261    (10.9%) 233    (10.3%)  205    (11.3%) 219    (11.4%)  
Region, n (%)       
North America 115    (4.8%) 102    (4.5%) 0.94 177    (9.8%) 208    (10.9%)  0.76 
Latin America 470    (19.6%) 454    (20.0%)  250    (13.8%) 259    (13.5%)  
Western Europe and other 505    (21.0%) 462    (20.3%)  520    (28.7%) 564    (29.4%)  
Central Europe 890    (37.1%) 843    (37.1%)  543    (30.0%) 550    (28.7%)  
Asia 420    (17.5%) 410    (18.1%)  322    (17.8%) 335    (17.5%)  
Systolic blood pressure, mm Hg 119 ± 15 120 ± 15 0.17 124 ± 16 123 ± 16 0.70 
Heart rate, beats/min 73 ± 12 72 ± 12 0.35 72 ± 12 72 ± 12 0.51 
Body mass index, kg/m2 28 ± 6 28 ± 6 0.29 28 ± 6 28 ± 5 0.06 
Serum creatinine, mg/dL 1.11 ± 0.29 1.12 ± 0.30 0.52 1.13 ± 0.31 1.13 ± 0.30 0.62 
Clinical features of heart failure       
Left ventricular ejection 
fraction, % 29 ± 6 29 ± 6 0.72 30 ± 6 30 ± 6 0.91 
Median BNP, pg/mL (IQR) 
255.1 [152.4, 
478.4] 257.6 [149.8, 496.6] 0.74 
244.2 [154.2, 
447.5] 252.5 [159.5, 449.6] 0.56 










NYHA functional class, n (%)       
I 118    (4.9%) 98     (4.3%) 0.72 91     (5.0%) 82     (4.3%)  0.008 
II 1623    (67.7%) 1551    (68.4%)  1298    (71.8%) 1447    (75.6%)  
III 639    (26.7%) 605    (26.7%)  410    (22.7%) 364    (19.0%)  
IV 17     (0.7%) 13     (0.6%)  10     (0.6%) 20     (1.0%)  
Ischemic etiology, n (%) 1369    (57.0%) 1274    (56.1%) 0.52 1161    (64.1%) 1232    (64.3%) 0.88 
Medical history, n (%)       
Hypertension 1645    (68.5%) 1605    (70.7%) 0.11 1326    (73.2%) 1364    (71.2%) 0.18 
Diabetes mellitus 811    (33.8%) 751    (33.1%) 0.60 645    (35.6%) 700    (36.5%) 0.55 
Atrial fibrillation 884    (36.8%) 820    (36.1%) 0.61 690    (38.1%) 697    (36.4%) 0.28 
Previous heart failure 
hospitalization 1633    (68.0%) 1559    (68.6%) 0.66 1034    (57.1%) 1048    (54.7%) 0.15 
Myocardial infarction 1013    (42.2%) 942    (41.5%) 0.61 803    (44.3%) 876    (45.7%) 0.39 
Stroke 211    (8.8%) 193    (8.5%) 0.72 159    (8.8%) 162    (8.5%) 0.73 
Treatment at randomization, n 
(%)       
Previous use of ACE inhibitor 1862    (77.6%) 1797    (79.1%) 0.20 1404    (77.5%) 1469    (76.7%) 0.55 
Previous use of ARB 542    (22.6%) 476    (21.0%) 0.18 421    (23.2%) 453    (23.6%) 0.77 
Diuretics 1980    (82.5%) 1898    (83.6%) 0.33 1395    (77.0%) 1465    (76.5%) 0.70 
Digitalis 839    (35.0%) 744    (32.8%) 0.11 477    (26.3%) 479    (25.0%) 0.35 
β-Blocker 2259    (94.1%) 2127    (93.7%) 0.51 1653    (91.2%) 1772    (92.5%) 0.16 
Implantable cardioverter-
defibrillator 361    (15.0%) 341    (15.0%) 0.98 259    (14.3%) 282    (14.7%) 0.71 
Cardiac resynchronization 







Table 3: Baseline characteristics according to baseline Digitalis 
 Digitalis (Yes) P value Digitalis (No) P value 
 Enalapril Sacubitril/valsartan  Enalapril Sacubitril/valsartan  
n (%) n=1316 (16) n=1223 (15)  n=2896 (34) n=2964 (35)   
Age, year 63 ± 12 62 ± 13 0.04 64 ± 11 65 ± 11 0.24 
Sex (female), n (%) 306    (23.3%) 267    (21.8%) 0.39 647    (22.3%) 612    (20.6%) 0.11 
Race, n (%)   0.80   0.98 
White 722    (54.9%) 666    (54.5%)  2059    (71.1%) 2097    (70.7%)   
Black 83     (6.3%) 71     (5.8%)  132    (4.6%) 142    (4.8%)   
Asian 331    (25.2%) 326    (26.7%)  419    (14.5%) 433    (14.6%)   
Other 180    (13.7%) 160    (13.1%)  286    (9.9%) 292    (9.9%)   
Region, n (%)   0.69   0.99 
North America 80     (6.1%) 83     (6.8%)  212    (7.3%) 227    (7.7%)   
Latin America 256    (19.5%) 243    (19.9%)  464    (16.0%) 470    (15.9%)   
Western Europe and other 208    (15.8%) 187    (15.3%)  817    (28.2%) 839    (28.3%)   
Central Europe 440    (33.4%) 382    (31.2%)  993    (34.3%) 1011    (34.1%)   
Asia 332    (25.2%) 328    (26.8%)  410    (14.2%) 417    (14.1%)   
Systolic blood pressure, mm 
Hg 120 ± 15 120 ± 14 0.96 122 ± 15 122 ± 15 0.28 
Heart rate, beats/min 75 ± 13 75 ± 12 0.84 72 ± 12 71 ± 12 0.35 
Body mass index, kg/m2 28 ± 6 27 ± 6 0.14 28 ± 5 28 ± 5 0.77 
Serum creatinine, mg/dL 1.12 ± 0.30 1.10 ± 0.29 0.09 1.12 ± 0.30 1.14 ± 0.30 0.04 
Clinical features of heart failure       
Left ventricular ejection 
fraction, % 29 ± 6 29 ± 6 0.87 30 ± 6 30 ± 6 0.36 
Median BNP, pg/mL (IQR) 259.1 [149.8, 519.6] 269.1 [156.7, 548.1] 0.17 245.1 [154.3, 447.9] 249.1 [153.8, 447.9] 0.90 










NYHA functional class, n (%)   0.08    
I 56     (4.3%) 42     (3.4%)  153    (5.3%) 138    (4.7%)  0.57 
II 865    (65.8%) 855    (69.9%)  2056    (71.1%) 2143    (72.5%)  
III 384    (29.2%) 312    (25.5%)  665    (23.0%) 657    (22.2%)  
IV 10     (0.8%) 14     (1.1%)  17     (0.6%) 19     (0.6%)  
Ischemic etiology, n (%) 656    (49.8%) 596    (48.7%) 0.57 1874    (64.7%) 1910    (64.4%) 0.83 
Medical history, n (%)       
Hypertension 850    (64.6%) 783    (64.0%) 0.77 2121    (73.2%) 2186    (73.8%) 0.66 
Diabetes mellitus 472    (35.9%) 410    (33.5%) 0.22 984    (34.0%) 1041    (35.1%) 0.36 
Atrial fibrillation 707    (53.7%) 637    (52.1%) 0.41 867    (29.9%) 880    (29.7%) 0.84 
Previous heart failure 
hospitalization 859    (65.3%) 786    (64.3%) 0.60 1808    (62.4%) 1821    (61.4%) 0.84 
Myocardial infarction 400    (30.4%) 366    (29.9%) 0.81 1416    (48.9%) 1452    (49.0%) 0.43 
Stroke 109    (8.3%) 102    (8.3%) 0.96 261    (9.0%) 253    (8.5%) 0.94 
Treatment at randomization, n 
(%)       
Previous use of ACE inhibitor 990    (75.2%) 928    (75.9%) 0.70 2276    (78.6%) 2338    (78.9%) 0.79 
Previous use of ARB 331    (25.2%) 298    (24.4%) 0.65 632    (21.8%) 631    (21.3%) 0.62 
Diuretics 1139    (86.6%) 1068    (87.3%) 0.56 2236    (77.2%) 2295    (77.4%) 0.84 
β-Blocker 1210    (91.9%) 1107    (90.5%) 0.20 2702    (93.3%) 2792    (94.2%) 0.16 
Mineralocorticoid antagonist 839    (63.8%) 744    (60.8%) 0.13 1561    (53.9%) 1527    (51.5%) 0.07 
Implantable cardioverter-
defibrillator 162    (12.3%) 145    (11.9%) 0.73 458    (15.8%) 478    (16.1%) 0.74 
Cardiac resynchronization 









Table 4: Baseline characteristics according to baseline ICD/CRT 
 
 ICD/CRT (Yes) P value ICD/CRT (No) P value 
 Enalapril Sacubitril/valsartan  Enalapril Sacubitril/valsartan  
n (%) n=620 (7) n=623 (7)  n=3592 (43) n=3564 (42)  
Age, year 65 ± 10 65 ± 10 0.84 64 ± 12 64 ± 12 0.78 
Sex (female), n (%) 93     (15.0%) 75     (12.0%) 0.17 860    (23.9%) 804    (22.6%) 0.13 
Race, n (%)       
White 536    (86.5%) 528    (84.8%) 0.86 2245    (62.5%) 2235    (62.7%)  0.62 
Black 39     (6.3%) 45     (7.2%)  176    (4.9%) 168    (4.7%)  
Asian 16     (2.6%) 13     (2.1%)  734    (20.4%) 746    (20.9%)  
Other 29     (4.7%) 37     (5.9%)  437    (12.2%) 415    (11.6%)  
Region, n (%)       
North America 158    (25.5%) 169    (27.1%) 0.87 134    (3.7%) 141    (4.0%)  0.67 
Latin America 26     (4.2%) 35     (5.6%)  694    (19.3%) 678    (19.0%)  
Western Europe and other 324    (52.3%) 304    (48.8%)  701    (19.5%) 722    (20.3%)  
Central Europe 99     (16.0%) 102    (16.4%)  1334    (37.1%) 1291    (36.2%)  
Asia 13     (2.1%) 13     (2.1%)  729    (20.3%) 732    (20.5%)  
Systolic blood pressure, 
mm Hg 118 ± 15 118 ± 14 0.40 122 ± 15 122 ± 15 0.48 
Heart rate, beats/min 69 ± 11 68 ± 10 0.59 73 ± 12 73 ± 12 0.08 
Body mass index, kg/m2 29 ± 5 29 ± 5 0.83 28 ± 6 28 ± 5 0.46 
Serum creatinine, mg/dL 1.24 ± 0.32 1.24 ± 0.31 0.30 1.10 ± 0.29 1.11 ± 0.29 0.81 
Clinical features of heart 
failure       
Left ventricular ejection 
fraction, % 27 ± 7 27 ± 6 0.48 30 ± 6 30 ± 6 0.27 
Median BNP, pg/mL (IQR) 
245.0 [162.9, 
434.9] 244.8 [158.4, 458.4] 0.69 
251.5 [151.6, 











NYHA functional class, n 
(%)       
I 18     (2.9%) 24     (3.9%) 0.02 191    (5.3%) 156    (4.4%)  0.80 
II 470    (75.8%) 461    (74.2%)  2451    (68.3%) 2537    (71.3%)  
III 129    (20.8%) 133    (21.4%)  920    (25.7%) 836    (23.5%)  
IV 3      (0.5%) 3      (0.5%)  24     (0.7%) 30     (0.8%)  
Ischemic etiology, n (%) 407    (65.6%) 425    (68.2%) 0.54 2123    (59.1%) 2081    (58.4%) 0.33 
Medical history, n (%)       
Hypertension 409    (66.0%) 430    (69.0%) 0.94 2562    (71.3%) 2539    (71.2%) 0.25 
Diabetes mellitus 252    (40.6%) 249    (40.0%) 0.85 1204    (33.5%) 1202    (33.7%) 0.81 
Atrial fibrillation 236    (38.1%) 234    (37.6%) 0.27 1338    (37.2%) 1283    (36.0%) 0.85 
Previous heart failure 
hospitalization 399    (64.4%) 416    (66.8%) 0.15 2268    (63.1%) 2191    (61.5%) 0.37 
Myocardial infarction 351    (56.6%) 364    (58.4%) 0.99 1465    (40.8%) 1454    (40.8%) 0.52 
Stroke 67     (10.8%) 62     (10.0%) 0.74 303    (8.4%) 293    (8.2%) 0.62 
Treatment at 
randomization, n (%)       
Previous use of ACE 
inhibitor 488    (78.7%) 517    (83.0%) 0.84 2778    (77.3%) 2749    (77.1%) 0.06 
Previous use of ARB 139    (22.4%) 107    (17.2%) 0.90 824    (22.9%) 822    (23.1%) 0.19 
Diuretics 522    (84.2%) 507    (81.4%) 0.46 2853    (79.4%) 2856    (80.1%) 0.19 
Digitalis 162    (26.1%) 145    (23.3%) 0.09 1154    (32.1%) 1078    (30.2%) 0.24 
β-Blocker 600    (96.8%) 601    (96.5%) 0.6 3312    (92.2%) 3298    (92.5%) 0.77 
Mineralocorticoid 
antagonist 361    (58.2%) 341    (54.7%) 0.03 2039    (56.8%) 1930    (54.2%) 0.21 
Cardiac resynchronization 




Table 5: Baseline characteristics according to Prior coronary revascularization 
 
 Prior coronary revascularization (Yes) P value Prior coronary revascularization (No) P value 
 Enalapril Sacubitril/valsartan  Enalapril Sacubitril/valsartan  
n (%) n=1291 (15) n=1349 (16)  n=2921(35) n=2838 (34)  
Age, year 65 ± 10 66 ± 10 0.26 63 ± 12 63 ± 12 0.36 
Sex (female), n (%) 176    (13.6%) 174    (12.9%) 0.58 777    (26.6%) 705    (24.8%) 0.13 
Race, n (%)       
White 996    (77.1%) 1061    (78.7%) 0.52 1785    (61.1%) 1702    (60.0%)  0.54 
Black 27     (2.1%) 29     (2.1%)  188    (6.4%) 184    (6.5%)  
Asian 183    (14.2%) 165    (12.2%)  567    (19.4%) 594    (20.9%)  
Other 85     (6.6%) 94     (7.0%)  381    (13.0%) 358    (12.6%)  
Region, n (%)       
North America 146    (11.3%) 171    (12.7%) 0.42 146    (5.0%) 139    (4.9%)  0.63 
Latin America 126    (9.8%) 143    (10.6%)  594    (20.3%) 570    (20.1%)  
Western Europe and other 430    (33.3%) 428    (31.7%)  595    (20.4%) 598    (21.1%)  
Central Europe 417    (32.3%) 451    (33.4%)  1016    (34.8%) 942    (33.2%)  
Asia 172    (13.3%) 156    (11.6%)  570    (19.5%) 589    (20.8%)  
Systolic blood pressure, 
mm Hg 120 ± 15 121 ± 15 0.15 122 ± 16 122 ± 15 0.74 
Heart rate, beats/min 70 ± 11 70 ± 12 0.99 73 ± 12 73 ± 12 0.25 
Body mass index, kg/m2 29 ± 5 28 ± 5 0.44 28 ± 6 28 ± 6 0.88 
Serum creatinine, mg/dL 1.18 ± 0.29 1.19 ± 0.31 0.25 1.09 ± 0.30 1.09 ± 0.29 0.99 
Clinical features of heart 
failure       
Left ventricular ejection 
fraction, % 29 ± 6 30 ± 6 0.03 29 ± 6 29 ± 6 0.82 
Median BNP, pg/mL 











NYHA functional class, n 
(%)       
I 57     (4.4%) 48     (3.6%) 0.63 152    (5.2%) 132    (4.7%)  0.07 
II 943    (73.0%) 1000    (74.3%)  1978    (67.9%) 1998    (70.5%)  
III 283    (21.9%) 291    (21.6%)  766    (26.3%) 678    (23.9%)  
IV 8      (0.6%) 6      (0.4%)  19     (0.7%) 27     (1.0%)  
Ischemic etiology, n (%) 1210    (93.7%) 1276    (94.6%) 0.34 1320    (45.2%) 1230    (43.3%) 0.16 
Medical history, n (%)       
Hypertension 961    (74.4%) 1022    (75.8%) 0.43 2010    (68.8%) 1947    (68.6%) 0.87 
Diabetes mellitus 593    (45.9%) 578    (42.8%) 0.11 863    (29.5%) 873    (30.8%) 0.31 
Atrial fibrillation 435    (33.7%) 424    (31.4%) 0.21 1139    (39.0%) 1093    (38.5%) 0.71 
Previous heart failure 
hospitalization 819    (63.4%) 831    (61.6%) 0.33 1848    (63.3%) 1776    (62.6%) 0.59 
Myocardial infarction 1035    (80.2%) 1092    (80.9%) 0.61 781    (26.7%) 726    (25.6%) 0.32 
Stroke 131    (10.1%) 123    (9.1%) 0.37 239    (8.2%) 232    (8.2%) 0.99 
Treatment at 
randomization, n (%)       
Previous use of ACE 
inhibitor 1029    (79.7%) 1094    (81.1%) 0.37 2237    (76.6%) 2172    (76.5%) 0.96 
Previous use of ARB 270    (20.9%) 260    (19.3%) 0.29 693    (23.7%) 669    (23.6%) 0.89 
Diuretics 1018    (78.9%) 1066    (79.0%) 0.92 2357    (80.7%) 2297    (80.9%) 0.81 
Digitalis 242    (18.7%) 249    (18.5%) 0.85 1074    (36.8%) 974    (34.3%) 0.05 
β-Blocker 1211    (93.8%) 1271    (94.2%) 0.65 2701    (92.5%) 2628    (92.6%) 0.85 
Mineralocorticoid 
antagonist 681    (52.7%) 663    (49.1%) 0.06 1719    (58.8%) 1608    (56.7%) 0.09 
Implantable cardioverter-
defibrillator 337    (26.1%) 352    (26.1%) 0.99 283    (9.7%) 271    (9.5%) 0.86 
Cardiac resynchronization 




Table 6: Baseline characteristics according to baseline beta-blocker dose (target dose ≥50% vs. <50%) 
 
 Beta-blocker target dose (≥50%) P value Beta-blocker target dose (<50%) P value 
 Enalapril Sacubitril/valsartan  Enalapril Sacubitril/valsartan  
n (%) n=1789 (21) n=1855 (22)  n=2123 (25) n=2044 (24)  
Age, year 64 ± 11 64 ± 11 0.75 64 ± 12 64 ± 12 0.94 
Sex (female), n (%) 387    (21.6%) 366    (19.7%) 0.16 496    (23.4%) 442    (21.6%) 0.18 
Race, n (%)       
White 1456    (81.4%) 1496    (80.6%) 0.89 1164    (54.8%) 1113    (54.5%)  0.96 
Black 96     (5.4%) 100    (5.4%)  103    (4.9%) 101    (4.9%)  
Asian 96     (5.4%) 110    (5.9%)  570    (26.8%) 563    (27.5%)  
Other 141    (7.9%) 149    (8.0%)  286    (13.5%) 267    (13.1%)  
Region, n (%)       
North America 179    (10.0%) 205    (11.1%) 0.84 104    (4.9%) 98     (4.8%)  0.97 
Latin America 240    (13.4%) 244    (13.2%)  423    (19.9%) 415    (20.3%)  
Western Europe and other 539    (30.1%) 556    (30.0%)  424    (20.0%) 393    (19.2%)  
Central Europe 742    (41.5%) 751    (40.5%)  602    (28.4%) 576    (28.2%)  
Asia 89     (5.0%) 99     (5.3%)  570    (26.8%) 562    (27.5%)  
Systolic blood pressure, 
mm Hg 123 ± 16 123 ± 15 
0.88 
120 ± 15 121 ± 15 0.06 
Heart rate, beats/min 72 ± 12 72 ± 12 0.15 73 ± 12 73 ± 12 0.60 
Body mass index, kg/m2 30 ± 6 30 ± 6 0.65 27 ± 5 27 ± 5 0.06 
Serum creatinine, mg/dL 1.13 ± 0.29 1.15 ± 0.29 0.14 1.11 ± 0.30 1.11 ± 0.30 0.95 
Clinical features of heart 
failure   
 
   
Left ventricular ejection 
fraction, % 30 ± 6 30 ± 6 
0.92 
29 ± 6 29 ± 6 0.07 

















NYHA functional class, n 
(%)   
 
   
I 67     (3.7%) 76     (4.1%) 0.35 126    (5.9%) 94     (4.6%)  0.05 
II 1230    (68.8%) 1309    (70.8%)  1489    (70.2%) 1480    (72.4%)  
III 472    (26.4%) 452    (24.4%)  497    (23.4%) 453    (22.2%)  
IV 18     (1.0%) 13     (0.7%)  8      (0.4%) 16     (0.8%)  
Ischemic etiology, n (%) 1070    (59.8%) 1131    (61.0%) 0.45 1277    (60.2%) 1217    (59.5%) 0.66 
Medical history, n (%)       
Hypertension 1365    (76.3%) 1400    (75.5%) 0.58 1406    (66.2%) 1375    (67.3%) 0.48 
Diabetes mellitus 666    (37.2%) 687    (37.0%) 0.93 690    (32.5%) 661    (32.3%) 0.89 
Atrial fibrillation 745    (41.6%) 770    (41.5%) 0.91 726    (34.2%) 625    (30.6%) 0.014 
Previous heart failure 
hospitalization 1154    (64.5%) 1170    (63.1%) 
0.39 
1341    (63.2%) 1268    (62.0%) 0.43 
Myocardial infarction 806    (45.1%) 852    (45.9%) 0.59 887    (41.8%) 860    (42.1%) 0.85 
Stroke 176    (9.8%) 160    (8.6%) 0.22 160    (7.5%) 170    (8.3%) 0.36 
Treatment at 
randomization, n (%)   
 
   
Previous use of ACE 
inhibitor 1419    (79.3%) 1503    (81.0%) 
0.18 
1625    (76.5%) 1551    (75.9%) 0.59 
Previous use of ARB 383    (21.4%) 355    (19.1%) 0.08 502    (23.6%) 499    (24.4%) 0.54 
Diuretics 1422    (79.5%) 1501    (80.9%) 0.24 1717    (80.9%) 1639    (80.2%) 0.52 
Digitalis 491    (27.4%) 478    (25.8%) 0.24 719    (33.9%) 629    (30.8%) 0.03 
Mineralocorticoid 
antagonist 1017    (56.8%) 1007    (54.3%) 
0.13 
1242    (58.5%) 1120    (54.8%) 0.01 
Implantable cardioverter-
defibrillator 377    (21.1%) 395    (21.3%) 
0.81 
223    (10.5%) 206    (10.1%) 0.59 
Cardiac resynchronization 
therapy 170    (9.5%) 177    (9.5%) 
0.86 
105    (4.9%) 104    (5.1%) 0.96 
Table 7 Primary endpoint (composite of death from cardiovascular causes or 
hospitalization for heart failure) and death from cardiovascular causes according to 
baseline treatment, history of coronary revascularization and baseline beta-blocker 
dose adjusted for baseline factors (region, age, sex, systolic blood pressure, heart 
rate, body mass index, serum creatinine, ejection fraction, NYHA class, ischemic 
etiology, NT-proBNP, history of hypertension, myocardial infarction, stroke, 
diabetes mellitus, previous hospitalization for heart failure, previous use of ACE 
inhibitor, ARB and when part of the subgroup, diuretic, digitalis, mineralocorticoid 
receptor antagonist and ICD use).   
 Primary end-point Cardiovascular death 



















































































PARADIGM-HF Investigators  
PARADIGM-HF Collaborators: Vanhaecke J, Ramires F, Katova T, Arnold M, Huang J, Gomez E, Belohlavek 
J, Refsgaard J, Lederballe O, Gonzalez A, Duarte YC, Rosenthal A, Peuhkurinen K, Hagege AA, Böhm M, 
Arango JL, Andersen K, Senni M, Erglis A, Petrulioniene Z, Llamas EB, Mosterd A, Cabrera W, Sibulo AS, 
Jr, Negrusz-Kawecka M, Silva-Cardoso J, Vinereanu D, Boytsov S, Wong R, Dukat A, Burgess L, Kim KS, 
Calvo C, Fu M, Chen CH, Kiatchoosakun S, Kozan O, Starling R, Teerlink J, Dargie H, Foley R, Francis GS, 
Komajda M, Pocock S, Barkoudah E, Bello N, Brahimi A, Charytan D, Duong C, Finn P, Hartley H, Vazir A, 
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